Patent application number | Description | Published |
20100015219 | PHARMACEUTICAL COMPOSITIONS OF ACTIVE SUBSTANCES DIFFICULT TO IMPROPERLY DIVERT FROM THEIR INTENDED ROUTE OF ADMINISTRATION - A solid pharmaceutical composition in the form of a gel capsule containing at least one active ingredient and also at least one gelling agent chosen from cellulose derivatives such as hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, ethylmethylcellulose, sodium carboxymethylcellulose (CMC) and calcium carboxymethylcellulose, and at least one disintegrating agent, the gelling agent and the disintegrating agent being present in a ratio by weight of 0.3 to 0.7/1 and the content by weight of gelling agent(s) being from 10% to 20% of the composition, and method for preparing same. | 01-21-2010 |
20140080875 | 3,4-DIAMINOPYRIDINE TARTRATE AND PHOSPHATE, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - The invention relates to 3,4-diaminopyridine salts, pharmaceutical compositions containing at least one of said salts and uses thereof for the treatment of botulism, myasthenia, myasthenic syndromes or fatigue. | 03-20-2014 |
20150353467 | 3,4-DIAMINOPYRIDINE TARTRATE AND PHOSPHATE, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - The invention relates to 3,4-diaminopyridine salts, pharmaceutical compositions containing at least one of said salts and uses thereof for the treatment of botulism, myasthenia, myasthenic syndromes or fatigue. | 12-10-2015 |
Patent application number | Description | Published |
20090262365 | OPTICAL DEVICE FOR ANALYZING A SCATTERING MEDIUM HELD BY A SUPPORT - An optical device intended for the analysis of a scattering medium, including at least one light source distant from the scattering medium and capable of providing an incident light beam intended to illuminate the scattering medium; at least one sensor capable of detecting a radiation emitted by the scattering medium; a support of the scattering medium at least partially non-absorbing for the incident light beam and the scattered radiation. All or part of the support is formed of a scattering material having a decreased scattering coefficient greater than 0.1 cm | 10-22-2009 |
20100102210 | METHOD AND DEVICE FOR MEASURING OPTICAL CHARACTERISTICS FO AN OBJECT - Method and device for measuring the multi-dimensional distribution of optical characteristics of an object, by carrying out the following operations:
| 04-29-2010 |
20110085721 | METHOD AND DEVICE FOR DIFFUSE EXCITATION IN IMAGING - The invention concerns a coupling device for at least one optical fibre ( | 04-14-2011 |
20110195029 | FLUORESCENT EMULSION - The invention relates to a fluorescent emulsion, to its uses and to labelling reagents comprising it. | 08-11-2011 |
20120193582 | BIMODAL ORGAN PHANTOM AND ASSOCIATED PRODUCTION METHOD - A phantom for medical imaging instrumentation, the phantom including a first hydrogel matrix, said matrix containing additives for simulating the optical and acoustic properties of a living organ or tissue. In the phantom, the additives include Indian ink or haemoglobin, silica powder and titanium dioxide powder. The phantom may contain a tumor simulator in solid or liquid form. It may also comprise several hydrogel matrices, each matrix including additives in different concentrations depending on the organ or tissue simulated. A method of producing the phantom includes one or more freeze-thaw cycles for optimizing the characteristics of the phantom. | 08-02-2012 |
Patent application number | Description | Published |
20140378022 | GENERATION OF BUILDING INSTRUCTIONS FOR CONSTRUCTION ELEMENT MODELS - A toy construction system comprising a set of toy construction elements with coupling means for releasably interconnecting the toy construction elements; and a data processing system comprising image capturing means, processing means, and display means, wherein the data processing system is adapted to capture an image of a partial toy construction model constructed from a subset of the toy construction elements; process the captured image to detect at least a position and an orientation of the partial toy construction model; identify a user selection indicative of a user selection of at least one of a set of subsequent construction elements, each subsequent construction element being connectable to the partial toy construction model; responsive to the detected position and orientation of the partial toy construction model, display on said display means a composite image comprising the captured image having superimposed an image of at least the selected subsequent construction element. | 12-25-2014 |
20140378023 | TOY CONSTRUCTION SYSTEM FOR AUGMENTED REALITY - A toy construction system comprising toy construction elements, the toy construction elements comprising coupling means for releasably interconnecting the toy construction elements, comprising one or more marker construction elements comprising such coupling means and each having a visual appearance recognisable by an image processing means, and a data processing system comprising image capturing means, image processing means, and display means, wherein the data processing system is adapted to capture an image of a toy construction model constructed from the toy construction elements, to process the captured image to detect at least a presence of at least one of the marker construction elements within the captured image; responsive to the detected marker construction element, to generate a computer-generated image; and to display on said display means a composite image comprising the captured image having superimposed the generated computer-generated image. | 12-25-2014 |
Patent application number | Description | Published |
20080274081 | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules - Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated by cytokines. | 11-06-2008 |
20090053147 | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules - Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated by cytokines. | 02-26-2009 |
20090123974 | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules - Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated by cytokines. | 05-14-2009 |
20090131318 | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules - Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated by cytokines. | 05-21-2009 |
20090238789 | Modified erythropoietin polypeptides and uses thereof - Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides. | 09-24-2009 |
20110052493 | USE OF POLYPEPTIDES OBTAINED THROUGH SYSTEMATIC MUTATIONS OF SINGLE AMINO ACIDS OF HUMAN AND NON-HUMAN BOX-A OF HMGB1 TO PREVENT AND/OR ANTAGONIZE PATHOLOGIES INDUCED BY HMGB1 - The present invention relates to polypeptide variants of the HMGB-1 high affinity binding domain Box-A (HMGB1 Box-A) or to a biologically active fragment of HMGB1 Box-A, which are obtained through systematic mutations of single amino acids of the wild-type HMGB1 Box-A protein and which show an increased resistance to proteases and which are therefore characterized by more favourable pharmacokinetic and pharmacodynamic profiles. Moreover, the present invention concerns the use of said polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and associated with RAGE. | 03-03-2011 |
20110130331 | Modified growth hormones - Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides. | 06-02-2011 |
20110142801 | PROTEASE RESISTANT MODIFIED INTERFERON-BETA POLYPEPTIDES AND THEIR USE IN TREATING DISEASES - Protease resistant modified interferon-beta polypeptides, pharmaceutical compositions and methods of treatment by administering the compositions are provided. The modified interferon-beta polypeptides are orally available; hence pharmaceutical compositions formulated for oral administration also are provided. | 06-16-2011 |
20120094906 | MODIFIED ERYTHROPOIETIN (EPO) POLYPEPTIDES THAT EXHIBIT INCREASED PROTEASE RESISTANCE AND PHARMACEUTICAL COMPOSITIONS THEREOF - Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides. | 04-19-2012 |
20120264686 | MODIFIED ERYTHROPOIETIN (EPO) POLYPEPTIDES THAT EXHIBIT INCREASED PROTEASE RESISTANCE AND PHARMACEUTICAL COMPOSITIONS THEREOF - Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides. | 10-18-2012 |
20130243855 | Modified coagulation factor IX polypeptides and use thereof for treatment - Provided are modified factor IX (FIX) polypeptides and methods of generating modified FIX polypeptides. Also provided are pharmaceutical compositions, including compositions formulation for oral administration, that contain the modified FIX polypeptides, and methods of treatment using modified FIX polypeptides. | 09-19-2013 |